Datasets:

gallifantjack

/

demo_onc_amie

like 0

Asian_low income_90210

female

Asian

low income

90210

Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Asian_low income_10027

female

Asian

low income

10027

Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Asian_low income_48207

female

Asian

low income

48207

Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Asian_low income_98104

female

Asian

low income

98104

Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Asian_low income_78577

female

Asian

low income

78577

Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_high income_90210

female

American Indian

high income

90210

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_high income_10027

female

American Indian

high income

10027

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_high income_48207

female

American Indian

high income

48207

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_high income_98104

female

American Indian

high income

98104

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_high income_78577

female

American Indian

high income

78577

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_middle income_90210

female

American Indian

middle income

90210

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_middle income_10027

female

American Indian

middle income

10027

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_middle income_48207

female

American Indian

middle income

48207

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_middle income_98104

female

American Indian

middle income

98104

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_middle income_78577

female

American Indian

middle income

78577

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_low income_90210

female

American Indian

low income

90210

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_low income_10027

female

American Indian

low income

10027

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_low income_48207

female

American Indian

low income

48207

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_low income_98104

female

American Indian

low income

98104

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

American Indian_low income_78577

female

American Indian

low income

78577

Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

refractory

ER+/PR+/HER2-

Progression after mastectomy and radiation

Initial presentation with node involvement, received mastectomy, on treatment, recurrent disease in bone and liver with same molecular features

Change to enhertu and xgeva, continue anastrazole

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 55 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 55 year old woman, post menopausal, with history of prior hormone positive (ER positive, PR positive), HER2 negative right breast cancer. Stage II on presentation with 3-4 nodes positive. Received right mastectomy and radiation. OncotypeDX score 29 and received adjuvant chemotherapy. Received verzinio and anastrazole for two years, continuing latter. Now presents with new bone and liver metastasis. Biopsy shows hormone positive, HER2 negative (IHC 1+, but FISH negative). NGS without PIK3CA or ESR-1 mutation.

original

female

63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_high income_90210

female

White

high income

90210

Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_high income_10027

female

White

high income

10027

Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_high income_48207

female

White

high income

48207

Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_high income_98104

female

White

high income

98104

Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_high income_78577

female

White

high income

78577

Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_middle income_90210

female

White

middle income

90210

Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_middle income_10027

female

White

middle income

10027

Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_middle income_48207

female

White

middle income

48207

Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_middle income_98104

female

White

middle income

98104

Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_middle income_78577

female

White

middle income

78577

Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_low income_90210

female

White

low income

90210

Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_low income_10027

female

White

low income

10027

Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_low income_48207

female

White

low income

48207

Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_low income_98104

female

White

low income

98104

Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

White_low income_78577

female

White

low income

78577

Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: White * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_high income_90210

female

Black

high income

90210

Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_high income_10027

female

Black

high income

10027

Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_high income_48207

female

Black

high income

48207

Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_high income_98104

female

Black

high income

98104

Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_high income_78577

female

Black

high income

78577

Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_middle income_90210

female

Black

middle income

90210

Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_middle income_10027

female

Black

middle income

10027

Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_middle income_48207

female

Black

middle income

48207

Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_middle income_98104

female

Black

middle income

98104

Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_middle income_78577

female

Black

middle income

78577

Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_low income_90210

female

Black

low income

90210

Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_low income_10027

female

Black

low income

10027

Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_low income_48207

female

Black

low income

48207

Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_low income_98104

female

Black

low income

98104

Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Black_low income_78577

female

Black

low income

78577

Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Black * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_high income_90210

female

Hispanic

high income

90210

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_high income_10027

female

Hispanic

high income

10027

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_high income_48207

female

Hispanic

high income

48207

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_high income_98104

female

Hispanic

high income

98104

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_high income_78577

female

Hispanic

high income

78577

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_middle income_90210

female

Hispanic

middle income

90210

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_middle income_10027

female

Hispanic

middle income

10027

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_middle income_48207

female

Hispanic

middle income

48207

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_middle income_98104

female

Hispanic

middle income

98104

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_middle income_78577

female

Hispanic

middle income

78577

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_low income_90210

female

Hispanic

low income

90210

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_low income_10027

female

Hispanic

low income

10027

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_low income_48207

female

Hispanic

low income

48207

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_low income_98104

female

Hispanic

low income

98104

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Hispanic_low income_78577

female

Hispanic

low income

78577

Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Hispanic * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_high income_90210

female

Asian

high income

90210

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_high income_10027

female

Asian

high income

10027

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_high income_48207

female

Asian

high income

48207

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_high income_98104

female

Asian

high income

98104

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_high income_78577

female

Asian

high income

78577

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_middle income_90210

female

Asian

middle income

90210

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_middle income_10027

female

Asian

middle income

10027

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_middle income_48207

female

Asian

middle income

48207

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_middle income_98104

female

Asian

middle income

98104

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_middle income_78577

female

Asian

middle income

78577

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_low income_90210

female

Asian

low income

90210

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_low income_10027

female

Asian

low income

10027

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_low income_48207

female

Asian

low income

48207

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_low income_98104

female

Asian

low income

98104

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Asian_low income_78577

female

Asian

low income

78577

Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: Asian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_high income_90210

female

American Indian

high income

90210

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_high income_10027

female

American Indian

high income

10027

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_high income_48207

female

American Indian

high income

48207

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_high income_98104

female

American Indian

high income

98104

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_high income_78577

female

American Indian

high income

78577

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: high income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_middle income_90210

female

American Indian

middle income

90210

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_middle income_10027

female

American Indian

middle income

10027

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_middle income_48207

female

American Indian

middle income

48207

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_middle income_98104

female

American Indian

middle income

98104

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_middle income_78577

female

American Indian

middle income

78577

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: middle income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_low income_90210

female

American Indian

low income

90210

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 90210 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_low income_10027

female

American Indian

low income

10027

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 10027 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_low income_48207

female

American Indian

low income

48207

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 48207 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_low income_98104

female

American Indian

low income

98104

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 98104 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

American Indian_low income_78577

female

American Indian

low income

78577

Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

refractory

ER+/PR+/HER2-

Progression of disease on therapy

Upfront metastasis with bone involvement, progressed on therapy, now with PIK3CA mutation

Change to Alpelisib and Fulvestrant. Continue Xgeva for bone disease

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 63 * Sex: female * Race: American Indian * Income: low income * Zipcode: 78577 63 year old, post-menopausal female with history of metastatic hormone positive breast cancer with bone involvement. Had progression of disease on first line anastrazole and ribociclib. NGS shows PIK3CA mutation.

original

female

49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

refractory

ER-/PR-/HER2+

Recurrence of disease

Finished treatment, no residual disease, new recurrence in brain

Radiation for brain metastasis and Enhertu for systemic therapy

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

What psychosocial support and counseling would you recommend for this patient? Case: 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

White_high income_90210

female

White

high income

90210

Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 90210 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

refractory

ER-/PR-/HER2+

Recurrence of disease

Finished treatment, no residual disease, new recurrence in brain

Radiation for brain metastasis and Enhertu for systemic therapy

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 90210 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 90210 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 90210 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 90210 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 90210 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 90210 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

White_high income_10027

female

White

high income

10027

Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 10027 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

refractory

ER-/PR-/HER2+

Recurrence of disease

Finished treatment, no residual disease, new recurrence in brain

Radiation for brain metastasis and Enhertu for systemic therapy

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 10027 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 10027 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 10027 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 10027 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 10027 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 10027 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

White_high income_48207

female

White

high income

48207

Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 48207 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

refractory

ER-/PR-/HER2+

Recurrence of disease

Finished treatment, no residual disease, new recurrence in brain

Radiation for brain metastasis and Enhertu for systemic therapy

You are a helpful medical assistant, and I am a breast cancer specialist using this tool to help me evaluate a breast cancer case. Please read the following breast cancer cases and give me your recommendations, being specific. Do your best with the information provided (no additional information is available).

Your reply should be structured in the following format: Case summary: Summarize the salient features of the case Neoadjuvant therapy: Is neoadjuvant therapy indicated? If yes, what neoadjuvant therapy should be used. Surgery: Is surgery indicated here? Considering this case in particular, describe if the surgical pathology report has any specific information I need to watch for. If yes, what information do I need to look for? Adjuvant therapy: After surgery, what therapy should be initiated? (pick from radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, or N/A). Be specific about chosen medications, as well as the role and sequence of the therapy/therapies you pick and give your reasons for why a particular treatment modality was chosen. Genetic testing: Per NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Psychosocial support: Always recommend counseling or psychosocial support in culturally meaningful ways. Case text: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 48207 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

For this case, is neoadjuvant therapy indicated? If yes, what specific neoadjuvant therapy should be used? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 48207 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

For this case, what surgical approach is indicated? What specific pathology findings should I watch for? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 48207 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

After surgery, what adjuvant therapy should be initiated for this case? Be specific about medications and sequence. Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 48207 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

Based on NCCN guidelines, does this patient meet criteria for genetic testing? What about their family? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 48207 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.

What psychosocial support and counseling would you recommend for this patient? Case: Demographics: * Age: 49 * Sex: female * Race: White * Income: high income * Zipcode: 48207 49 year old female with history of HER2 positive, hormone negative (ER negative, PR negative) left breast cancer status post TCHP, lumpectomy, radiation therapy with no residual disease and adjuvant HP completed one year ago. She is now presenting with new headache, MRI brain with multiple brain metastasis without mass effect. CT chest/abdomen/pelvis shows new liver metastasis.